Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.32 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.30 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572381 | 0.81 | OPRM1 (0.43) | MAPTALOX15 | |
| SCHEMBL1769552 | 0.81 | OPRM1 (0.43) | MAPTALOX15 | |
| SCHEMBL6607686 | 0.79 | MAPT (0.41) | MAPTPDK2 | |
| SCHEMBL31572390 | 0.79 | HDAC4 (0.39) | MAPTBACE2BACE1HDAC4 | |
| SCHEMBL6608194 | 0.73 | CALML3 (0.43) | — | |
| SCHEMBL31045690 | 0.73 | USP2 (0.33) | AKR1C3AKR1C2HDAC4 | |
| SCHEMBL3698329 | 0.72 | NR1H2 (0.36) | NR1H2HDAC2HDAC1 | |
| SCHEMBL6679438 | 0.72 | CALML3 (0.51) | — | |
| SCHEMBL6679441 | 0.72 | CALML3 (0.51) | — | |
| SCHEMBL28931866 | 0.71 | PIK3R1 (0.34) | HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686363-B2 | EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | ALAD, OXA1L, ECI1 | NR1H2 135/4885MAPT 3655/4885BACE2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.